DOCSLIB.ORG
Explore
Sign Up
Log In
Upload
Search
Home
» Tags
» PDE5 inhibitor
PDE5 inhibitor
Phosphodiesterase-5 Inhibitors and the Heart: Heart: First Published As 10.1136/Heartjnl-2017-312865 on 8 March 2018
Mechanisms of Action of PDE5 Inhibition in Erectile Dysfunction
Caffeine and Adenosine
Phosphodiesterase (PDE)
Phosphodiesterase Type 5 Inhibitors for the Treatment of Erectile Dysfunction in Patients with Diabetes Mellitus
Alcohol-Induced Retrograde Memory Impairment in Rats: Prevention by Caffeine
The Effects of the Combined Use of a PDE5 Inhibitor and Medications for Hypertension, Lower Urinary Tract Symptoms and Dyslipidemia on Corporal Tissue Tone
Gene Polymorphism on Response to Sildenafil Therapy In
Clinical Pharmacology of Phosphodiesterase 5 Inhibitors in Erectile Dysfunction
PDE5 INHIBITOR POWDERS Sildenafil Powder, Tadalafil Powder
Cardiovascular Implications in the Use of PDE5 Inhibitor Therapy
(Cgki) and PDE5 in the Regulation of Ang II-Induced Cardiac Hypertrophy and Fibrosis
Erectile Dysfunction Julio R
WO 2009/154562 Al
Medical Diagnosis and Treatment Methods in Basic Medical Sciences
Reference ID: 4194824 FULL PRESCRIBING INFORMATION
Phosphodiesterase Type 5 Inhibitors, Topical Prostaglandin Quantity
Time Course of the Interaction Between Tadalafil and Nitrates
Top View
CONTRAINDICATIONS------• Renal Impairment: No Dose Adjustments Required (Including Severe • Use with Organic Nitrates
Viagra) Tadalafil (Cialis
Tadalafil: a Long-Acting PDE5 Inhibitor for the Management of Erectile Dysfunction
PDE5 Inhibitors (Tadalafil, Sildenafil, Vardenafil)
Modulation of High Affinity ATP-Dependent Cyclic Nucleotide
PDE5 Inhibitors in Type 2 Diabetes Cardiovascular Complications
PDE5 Inhibitors Beyond Erectile Dysfunction
(12) United States Patent (10) Patent No.: US 8,946,284 B2 Bristow Et Al
Potency, Selectivity, and Consequences of Nonselectivity of PDE Inhibition
Phosphodiesterase Inhibitors Say NO to Alzheimer's Disease
Is There a Space to Improve the Treatment of Erectile Dysfunction in the Next Years?
PDE5 Inhibitors (Erectile Dysfunction)
Cgmp Via PKG Activates 26S Proteasomes and Enhances Degradation of Proteins, Including Ones That Cause Neurodegenerative Diseases
Zaprinast, a Well-Known Cyclic Guanosine Monophosphate-Specific
The Use of Vasoactive Drugs in the Treatment of Male Erectile Dysfunction: Current Concepts
A Review of Phosphodiesterase Type 5 Inhibitors
Molecular Mechanisms That Could Contribute to Prolonged Effectiveness of PDE5 Inhibitors to Improve Erectile Function
VIAGRA® (Sildenafil Citrate) Tablets
Erectile Dysfunction: a Primer for in Office Management
Saurashtra University Re – Accredited Grade ‘B’ by NAAC (CGPA 2.93)
Pharmakologische Ansätze Einer Proteinkinase A-Aktivierung Zur Hemmung Der Mitogenese Glatter Gefäßmuskelzellen
An Integrative Approach for Improved Assessment of Cardiovascular Safety Data S
Male Sexual Dysfunction
Possible Beneficial Actions of Caffeine in SARS-Cov-2
Erectile Dysfunction and Hypertension
Erectile Dysfunction[Version 1; Peer Review: 2 Approved]
Role of Phosphodiesterase in the Biology and Pathology of Diabetes
Feedback Control Through Cgmp-Dependent Protein Kinase Contributes to Differential Regulation and Compartmentation of Cgmp in Rat Cardiac Myocytes Liliana R.V
Homocysteine and Copper Interact to Promote Type 5 Phosphodiesterase Expression in Rabbit Cavernosal Smooth Muscle Cells
The Phosphodiesterase Inhibitory Selectivity and the in Vitro and in Vivo Potency of the New PDE5 Inhibitor Vardenafil
EAU Guidelines on Male Sexual Dysfunction 2015 V2
The Role of Cgmp on Adenosine A1 Receptor-Mediated Inhibition of Synaptic Transmission at the Hippocampus
Therapeutic Strategies for Optimizing PDE-5 Inhibitor Therapy in Patients with Erectile Dysfunction Considered Difficult Or Challenging to Treat